Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Tremelimumab
Therapeutic Area : Oncology
Study Phase : Phase II
Recipient : Center Eugene Marquis
Deal Size : Inapplicable
Deal Type : Inapplicable
SIRT Followed by Immunotherapy for Hepatocellular Carcinoma with Portal Vein Thrombosis
Details : Tremelimumab is a Antibody drug candidate, which is currently being evaluated in Phase II clinical studies for the treatment of Carcinoma, Hepatocellular.
Product Name : Undisclosed
Product Type : Antibody, Unconjugated
Upfront Cash : Inapplicable
August 14, 2025
Lead Product(s) : Tremelimumab
Therapeutic Area : Oncology
Highest Development Status : Phase II
Recipient : Center Eugene Marquis
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Colchicine
Therapeutic Area : Cardiology/Vascular Diseases
Study Phase : Phase IV
Recipient : Vivek Reddy
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Colchicine is a Plant Extract/Herbal drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of Atrial Fibrillation.
Product Name : Undisclosed
Product Type : Plant Extract/Herbal
Upfront Cash : Inapplicable
January 09, 2025
Lead Product(s) : Colchicine
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Phase IV
Recipient : Vivek Reddy
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Paclitaxel
Therapeutic Area : Cardiology/Vascular Diseases
Study Phase : Approved FDF
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Boston Scientific Receives FDA Approval for the AGENT Drug-Coated Balloon
Details : AGENT Drug-Coated Balloon is a paclitaxel-coated catheter delivering a therapeutic dose to treat coronary in-stent restenosis in patients with coronary artery disease.
Product Name : AGENT™ Drug-Coated Balloon
Product Type : Cytotoxic Drug
Upfront Cash : Inapplicable
March 01, 2024
Lead Product(s) : Paclitaxel
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Approved FDF
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Furosemide
Therapeutic Area : Cardiology/Vascular Diseases
Study Phase : Phase IV
Recipient : Heart Center Research, LLC
Deal Size : Inapplicable
Deal Type : Inapplicable
Diuretics vs. Afterload Reduction for Treatment of HeartLogic Alerts
Details : Furosemide is a Other Small Molecule drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of Heart Failure.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
January 23, 2024
Lead Product(s) : Furosemide
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Phase IV
Recipient : Heart Center Research, LLC
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Prasugrel
Therapeutic Area : Cardiology/Vascular Diseases
Study Phase : Phase IV
Recipient : Kindai University
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Prasugrel is a Other Small Molecule drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of ST Elevation Myocardial Infarction.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
February 02, 2023
Lead Product(s) : Prasugrel
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Phase IV
Recipient : Kindai University
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Polidocanol
Therapeutic Area : Cardiology/Vascular Diseases
Study Phase : Phase IV
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Varithena Versus Endothermal Ablation of the Great Saphenous Vein (VERITAS)
Details : Polidocanol is a Other Small Molecule drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of Varicose Veins.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
April 06, 2022
Lead Product(s) : Polidocanol
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Phase IV
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Yttrium Radioisotopes
Therapeutic Area : Oncology
Study Phase : Phase II
Sponsor : Biocompatibles UK
Deal Size : Inapplicable
Deal Type : Inapplicable
TheraSphere With Durvalumab and Tremelimumab for HCC
Details : Yttrium-90 is a Other Small Molecule drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Carcinoma, Hepatocellular.
Product Name : Undisclosed
Product Type : Radiolabeled Compound
Upfront Cash : Inapplicable
October 01, 2021
Lead Product(s) : Yttrium Radioisotopes
Therapeutic Area : Oncology
Highest Development Status : Phase II
Sponsor : Biocompatibles UK
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : TheraSphere (Yttrium-90 Glass Microspheres) is a drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Carcinoma, Hepatocellular.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Inapplicable
August 23, 2021
Lead Product(s) : Heparin Sodium
Therapeutic Area : Cardiology/Vascular Diseases
Study Phase : Phase IV
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : The trial, which will follow patients for one year, will assess whether treatment with the EKOS system in combination with anticoagulation is associated with a significant reduction in adverse events compared to anticoagulation alone, within seven days o...
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
August 04, 2021
Lead Product(s) : Heparin Sodium
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Phase IV
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Undisclosed
Therapeutic Area : Urology
Study Phase : Undisclosed
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
REZŪM vs. Dual Drug Therapy for Symptomatic Benign Prostatic Hyperplasia in Sexually Active Men
Details : This drug candidate is currently being evaluated in clinical studies for the treatment of Prostatic Hyperplasia.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Inapplicable
April 09, 2021
Lead Product(s) : Undisclosed
Therapeutic Area : Urology
Highest Development Status : Undisclosed
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable